| DB ID | MyCo_5568 |
| Title | Usefulness of 1,3 Beta-D-Glucan Detection in non-HIV Immunocompromised Mechanical Ventilated Critically Ill Patients with ARDS and Suspected Pneumocystis jirovecii Pneumonia |
| Year | 2017 |
| PMID | 28378239 |
| Fungal Diseases involved | Pneumocystis jirovecii pneumonia |
| Associated Medical Condition | Non-HIV-AIDS Immunocompromised Mechanical Ventilated Critically Ill Patients with acute respiratory distress syndrome |
| Genus | Pneumocystis |
| Species | jirovecii |
| Organism | Pneumocystis jirovecii |
| Ethical Statement | This study was reviewed and approved by the ethics committee of the university hospital (University Hospital Technische Universita ¨t Mu ¨nchen, Germany.), and all data were processed anonymously. Need for informed consent was waived for this analysis. |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Germany |
| Cohort | This observational study was conducted at the medical ICU of the University Hospital Technische Universita ¨t Mu ¨nchen, Germany. All immunocompromised patients (18 years of age or older) without HIV with ARDS and suspected PCP between December 2014 and December 2015 were included. All patients with respiratory failure received bronchoalveolar lavage (BAL) and computed tomography of the chest. |
| Cohort No. | 50 |
| Age Group | > 18 |
| P Value | None |
| Sensitivity | 0.98 |
| Specificity | 0.86 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Pneumocystis jirovecii pneumonia (PCP) is a major cause of disease in immunocompromised individuals. Immunocompromised patients, particularly critically ill, are at increased risk for Pneumocystis jirovecii pneumonia (PCP). PCP still remains a serious and potentially life threatening infection linked with a high morbidity and mortality. Incidence of PCP is increasing due to wide spread use of immune-suppressants. In immunosuppressed critically ill patients, PCP presents in nearly 10% as acute respiratory distress syndrome (ARDS). Without appropriate antibiotic therapy, the mortality from PCP in non-HIV-infected patients rises up to 90%. However, early identification of PCP is still challenging, especially in critically ill. Not only the patients’ complexity, moreover, accompanying signs and symptoms are in most cases nonspecific and may not be present until the disease is advanced or disseminated. |
| Technique | PCR |
| Analysis Method | Positive PCR (pPCR) |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | PCR, FDA approved Fungitell assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
